Substance and claimed effects

Heavy menstrual bleeding (HMB), historically termed menorrhagia, is excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life NICE 2018. The objective threshold from the Hallberg population study is >80 mL per cycle (95th percentile of 476 Swedish women) Hallberg 1966; modern definitions are subjective and quality-of-life-based, because objective measurement is impractical outside research NICE 2018. The entry's scope is HMB in adult women of reproductive age — the symptom, its objective and subjective definitions, the structural and systemic causes catalogued under FIGO PALM-COEIN, and the downstream consequences: iron depletion (with and without anemia), energy and cognitive cost, daily and work impact, and quality-of-life burden. Claimed effects across catalogue dimensions: substantial drag on energy and focus via iron deficiency, meaningful short-term health burden, mood and quality-of-life cost, and — once recognised and treated — large reversibility of all of the above.

Evidence by addressing question

Mechanism

HMB is mechanism-plural; FIGO's PALM-COEIN framework sorts causes into structural (Polyps, Adenomyosis, Leiomyoma, Malignancy/hyperplasia) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not otherwise classified). The two highest-prevalence structural causes:

• Leiomyomas (fibroids) — benign monoclonal smooth-muscle tumours of the myometrium, estrogen- and progesterone-responsive. Present in roughly 25% of reproductive-age women on imaging; symptomatic in a substantial minority Stewart 2015Donnez 2016. Submucosal and intramural fibroids drive HMB via expanded endometrial surface area, distortion of vasculature, impaired myometrial contraction, and altered local hemostasis Stewart 2015.
• Adenomyosis — ectopic endometrial glands and stroma within the myometrium. Prevalence estimates range 20–35% on histology after hysterectomy and on modern imaging criteria; classic triad is HMB, dysmenorrhea, and an enlarged tender uterus Vannuccini 2017. Transvaginal ultrasound has reached sensitivity/specificity comparable to MRI for diagnosis Vannuccini 2017.

Non-structural mechanisms with meaningful prevalence: ovulatory dysfunction (PCOS, perimenopause, thyroid disease — unopposed estrogen producing thickened, irregularly shed endometrium Krassas 2010); endometrial-level dysregulation (altered prostaglandin balance and impaired local hemostasis); iatrogenic (copper IUDs, anticoagulants); and inherited bleeding disorders, most commonly von Willebrand disease James 2009.

Evidence (epidemiology and burden)

Prevalence depends sharply on definition: objective measurement (>80 mL/cycle by alkaline-hematin) yields 9–14%; subjective self-report yields 20–52%, with one population-based UK study at 15.2% under the NICE quality-of-life definition NICE 2018Hallberg 1966. Women's perception of their own bleeding correlates poorly with measured loss: only 40–50% of women who report HMB exceed the 80 mL threshold, and conversely many women who do exceed it consider their periods normal Higham 1990. The PBAC chart (Higham 1990) — a pictorial scoring tool with ≥100 the operational cutoff — achieves >80% sensitivity and specificity for objectively-measured menorrhagia and remains the standard semi-quantitative research tool. Population-level burden: in the UK, ~1.5 million GP consultations per year for menstrual complaints, with direct annual costs exceeding £65 million NICE 2018. In the US, estimated annual direct cost ~$1 billion and indirect cost (work absence, productivity) up to $12 billion Liu 2007Frick 2009.

Stakes — downstream consequences

HMB is the leading cause of iron deficiency and iron-deficiency anemia in premenopausal women in high-income countries Mansour 2021. The pathway has two stages worth separating:

• Iron deficiency without anemia appears first, as ferritin stores deplete to maintain hemoglobin. Symptoms appear well before hemoglobin falls below the anemia threshold: persistent fatigue, exercise intolerance, brain fog and reduced cognitive performance, hair shedding, restless legs, palpitations, and impaired mood Mansour 2021. In adolescents with HMB, fewer than half of iron-deficient cases are detected by hemoglobin alone — ferritin is the more sensitive marker Powers 2017.
• Iron-deficiency anemia follows when bleeding outpaces repletion. Prevalence among women with HMB ranges 35–60% depending on population Mansour 2021Powers 2017. In a Swedish cohort with von Willebrand disease and HMB, 45% had ferritin <30 μg/L and 18% had hemoglobin <12 g/dL.

Functional impact, separable from anemia: women with HMB report ~9 days/year of lost productivity (mostly presenteeism — showing up but accomplishing less), 33% mean productivity drop on bleeding days, restricted social and physical activity, sleep disruption from overnight changing, and meaningful anxiety/depression burden tied to the symptom itself Schoep 2019Liu 2007. Sexual-function and relationship effects are documented in qualitative studies.

Protocol — diagnostic workup and treatment

Diagnostic workup per NICE 2018 and ACOG 2019: history (PBAC if formalising), full blood count and ferritin (always — even when not visibly anemic), TSH if ovulatory dysfunction suspected, transvaginal ultrasound for structural causes, endometrial biopsy in women ≥45 or with persistent HMB unresponsive to treatment or with risk factors for hyperplasia/malignancy. Coagulation screen — including von Willebrand factor — when HMB has been present since menarche, in adolescents, with personal/family bleeding history, or with negative imaging.

First-line medical treatment is the levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg — Mirena/Liletta). The ECLIPSE primary-care RCT (Gupta 2013) randomised 571 women to LNG-IUS or usual medical treatment; LNG-IUS produced significantly greater improvements in Menorrhagia Multi-Attribute Scale scores at 2 years, sustained out to 10-year follow-up (Kai 2022). Cochrane meta-analysis: LNG-IUS reduces menstrual blood loss by 71–95% versus baseline and is superior to oral medical alternatives Bofill Rodriguez 2020. Other medical options:

• Tranexamic acid (antifibrinolytic, oral, 1 g three to four times daily during menses): blood-loss reduction 34–59% versus placebo; Lukes 2010 RCT showed 40.4% reduction (vs. 8.2% placebo, p<0.001) and significant improvement in patient-reported limitations on social, physical, and work activity.
• NSAIDs (mefenamic acid 500 mg three times daily, naproxen): 20–50% blood-loss reduction; less effective than LNG-IUS and tranexamic acid but addresses dysmenorrhea concurrently Bofill Rodriguez 2019.
• Combined hormonal contraceptives: blood-loss reduction ~35–70%; first-line when contraception is also desired.
• Oral progestins: high-dose for acute control; less effective than LNG-IUS for chronic management.

Surgical options after medical failure or when fertility preservation is not required:

• Endometrial ablation — outpatient, ~85% bleeding satisfaction at short-term follow-up; one-third require further intervention within ~5 years; hysterectomy avoidance ~90% at 1–2 years, decaying over time Cooper 2019.
• Myomectomy / uterine artery embolisation — fibroid-specific, fertility-sparing where relevant Stewart 2015.
• Hysterectomy — definitive; reserved for failure of less-invasive options or where pathology demands it. The HEALTH trial (Cooper 2019) showed laparoscopic supracervical hysterectomy modestly outperformed second-generation endometrial ablation on patient-reported satisfaction at 15 months, at the cost of greater procedural morbidity.

Iron repletion runs in parallel to source treatment — oral ferrous sulphate or equivalent for mild–moderate deficiency, intravenous iron (ferric carboxymaltose, ferric derisomaltose) for severe deficiency, intolerance, or rapid repletion need Mansour 2021.

Contraindications and red flags

Red flags requiring expedited evaluation: postcoital bleeding, intermenstrual bleeding (especially after age 40), postmenopausal bleeding, pelvic mass on exam, age ≥45 with new HMB (rule out hyperplasia/malignancy via biopsy), hemodynamic instability with acute bleed. Tranexamic acid is contraindicated in active thromboembolic disease and in women with strong VTE history; LNG-IUS contraindicated in active pelvic infection, undiagnosed uterine bleeding, suspected gynecologic malignancy, current breast cancer. NSAIDs contraindicated in peptic ulcer disease, severe renal impairment, certain bleeding diatheses. Combined hormonal contraceptives contraindicated in women with migraine with aura, history of VTE, smoking ≥35, and several cardiovascular conditions.

Misconceptions

The dominant misconception is that heavy periods are normal — particularly in families where mother and sisters bled heavily, since pattern inheritance reinforces the read of "this is just how my body is" James 2009. Qualitative work shows women delay presentation for years, often citing normalisation as the primary reason; ~80% of women with HMB do not seek medical care for it. Other misconceptions: that ferritin doesn't matter if hemoglobin is normal (it does — symptoms appear well before frank anemia) Powers 2017; that hysterectomy is the only fix (LNG-IUS makes most cases medically manageable) Gupta 2013; that hormonal IUDs are only for contraception (the 52 mg LNG-IUS is FDA-approved specifically for HMB).

Failure modes

Common failure patterns: hemoglobin-only screening missing iron-deficient women with normal Hb; structural workup skipped, missing fibroids or polyps; coagulopathy workup skipped in women with lifelong HMB, missing von Willebrand disease (5–24% prevalence among women with chronic HMB) James 2009; tranexamic acid prescribed but used as-needed rather than scheduled across menses; LNG-IUS discontinued early during the 3–6 month bleeding-pattern adjustment phase that precedes the major reduction Bofill Rodriguez 2020; iron repletion stopped when hemoglobin normalises, before ferritin stores are refilled (recurrence within months).

Audience

HMB is by definition a condition of women with menstrual cycles — premenarchal and postmenopausal bleeding are different entities with different workups. Within reproductive-age women, age stratifies the workup: adolescents need coagulopathy screening (von Willebrand disease prevalence ~13–34% in adolescents with HMB) ACOG 2019; perimenopausal women (40–55) need endometrial sampling. The entry is scoped to adult women 18–55.

Credibility range

Optimist case

HMB is one of the most treatable common conditions in women's health. The 80 mL/cycle definition has 60 years of population-data backing; the PBAC chart is a validated practical surrogate; PALM-COEIN gives a comprehensive causal framework; multiple Cochrane-level interventions reduce bleeding by 40–95%; primary-care RCTs (ECLIPSE) demonstrate effectiveness in routine NHS settings out to 10 years. The downstream iron-deficiency cost is well-characterised, and iron repletion is cheap and effective. The under-recognition is largely a healthcare-utilisation problem (women don't present) rather than a treatment-efficacy problem.

Skeptic case

The category is partly an artefact of measurement. Subjective definitions yield prevalence rates anywhere from 15% to 52%; objective measurement is impractical outside trials; the PBAC chart is observer-dependent. Many of the trial endpoints are surrogate (mL/cycle, PBAC score) rather than felt-experience; the gap between bleeding reduction and quality-of-life improvement is variable across women. LNG-IUS has a real expulsion rate (~5–10%) and a real early-side-effects burden (irregular bleeding, hormonal symptoms) that drives discontinuation. Endometrial ablation has a substantial reintervention rate. The iron-deficiency-without-anemia symptom story is more contested than the anemia story — fatigue is multifactorial and ferritin's symptom threshold isn't universally agreed.

Author's call

The substance, its consequences, and its treatability are well-established — high evidence (5/5). The diagnostic side is contested mostly at the edges (where the cutoff sits, which subjective measure to use), not on the substance. The skeptic's reasonable points argue for individualised choice between LNG-IUS / tranexamic acid / surgery rather than against treatment per se. The under-recognition fact is the lever: a reader who learns that heavy periods are a treatable medical condition, not a personality trait, can act. Treat as know + decide: recognise it, get the workup, choose the treatment with a clinician.

Stakeholder and incentive map

• Manufacturers — Bayer (Mirena), Pfizer (Lysteda — branded tranexamic acid), AbbVie (Oriahnn — elagolix combination), Myovant/Sumitomo (Myfembree — relugolix combination) all market HMB-specific products. Incentive: maximise prescription. Commercial bias in funded trials is real but the underlying mechanism + Cochrane evidence is independent.
• Guidelines bodies — NICE, ACOG, FIGO, RCOG have aligned recommendations. NICE's QoL-based definition has shifted clinical practice toward patient-centered diagnosis.
• Clinicians — primary care undertreats (limited time, normalisation by both patient and clinician); gynecology sees the referrals later in the trajectory. Surgical specialties have a structural bias toward procedural intervention.
• Patient community — strong online presence (r/menorrhagia, period-tracking apps with HMB modules) increasingly normalising the "this is treatable" message; advocacy from women's-health organisations (Wear White Again, Period.org).
• Counter — historical undertreatment is itself a stakeholder force: a default frame of "periods are uncomfortable for everyone" that older healthcare provider cohorts may carry.

Population variability

• Adolescents — coagulopathy prevalence highest; up to ~34% have an underlying bleeding disorder when systematically tested ACOG 2019. Out of scope for this entry but flagged.
• Perimenopausal women (40–55) — fibroids and adenomyosis prevalence peaks; ovulatory dysfunction common; endometrial cancer risk rises so biopsy threshold drops.
• Women with PCOS — anovulatory cycles produce unopposed estrogen and irregular heavy episodes; progestin therapy addresses both.
• Black women — fibroid prevalence ~3× higher than white women, earlier onset, larger fibroids, more symptomatic Stewart 2015. HMB burden is correspondingly higher.
• Women with inherited bleeding disorders — von Willebrand disease (5–24% of HMB referrals) James 2009, platelet function disorders, factor deficiencies. Standard medical treatment efficacy is broadly preserved with hematology co-management.
• Postpartum women — adenomyosis and fibroids often progress with parity; HMB onset or worsening post-childbirth is common.

Knowledge gaps

• The ferritin threshold below which iron deficiency causes symptoms — research moving from <15 μg/L toward <30–50 μg/L but consensus incomplete.
• Long-term comparative effectiveness data for newer GnRH-antagonist combinations (relugolix, elagolix) vs. LNG-IUS for fibroid-associated HMB.
• How much of HMB-attributable fatigue is iron-mediated versus blood-loss-volume-mediated versus cycle-disruption-mediated.
• The natural history of HMB into perimenopause — when to treat and when to manage symptomatically.
• Pragmatic biomarkers beyond ferritin (transferrin saturation, soluble transferrin receptor) that better track functional iron status.

Scope vs. brief. Brief named: definitions, treatable causes including fibroids and adenomyosis, effects on iron stores, energy, daily function, quality of life. Article covers all six. Causes are treated comprehensively via PALM-COEIN framing rather than only fibroids + adenomyosis; this is the editorially honest read of the brief's "treatable causes including..." phrasing.

Adolescent HMB excluded. Brief specifies adult women. Adolescent HMB has a different presentation profile (much higher coagulopathy prevalence), different first-line workup emphasis (von Willebrand screening before structural workup), and different treatment menu (LNG-IUS less commonly used). Flagged in research §population variability; warrants its own entry.

Pregnancy-related bleeding, postmenopausal bleeding excluded. These are distinct entities with different workups (cancer rule-out for postmenopausal, obstetric for pregnancy). The contraindications section's red-flag list points readers with postmenopausal bleeding to a faster clinical track.

Rating difficulties.

• Beauty dimensions scored 1. Hair shedding from iron deficiency is real and reverses with treatment, but the magnitude is modest and the timescale is months. Considered 2 on beauty_cumulative but the effect is slow and not always reliably reversible past a threshold; 1 reads more honest.
• Action = know vs. decide. The reader-facing action is recognition (the brief's emphasis on under-diagnosis and women not knowing they qualify); treatment selection is then a decide. Chose know because the upstream action is the bigger lever — most women never reach the decide step.
• Cadence = as-needed. The action is a one-off recognition-and-evaluation. Treatment itself is daily (iron), episodic (tranexamic acid), or passive (LNG-IUS), but the entry-level action is once.
• Audience age band excludes 60+. By definition HMB is in menstruating women. Postmenopausal bleeding is a separate, oncology-flagged entity. Including 60+ would broaden the audience signal misleadingly.

Iron deficiency without anaemia — load-bearing in the stakes section. The ferritin-vs-haemoglobin distinction is the single most actionable thing in the article for readers whose bloodwork has been called "normal" for years. Considered making this a separate entry; decided it belongs inside HMB because HMB is the dominant upstream cause and the recognition-action chain only works if the iron story is told here. A separate iron-deficiency-without-anaemia entry is flagged for the backlog (referenced in out-of-scope).

Future-link candidates (referenced in the closing addressing section, not yet existing):

• iron-deficiency-without-anemia
• iron-supplementation
• dysmenorrhea
• endometriosis
• uterine-fibroids (this entry overlaps but fibroid-specific treatment menu warrants its own entry)
• adenomyosis (same — sibling entry candidate)
• pcos
• perimenopause

Separate-entry candidates surfaced during writing: uterine fibroids and adenomyosis are both substantial enough to warrant their own entries; this one frames them as upstream causes and points outward. The fibroid-treatment menu (myomectomy, UAE, GnRH-modulators including relugolix and elagolix combinations) is not unpacked here for that reason.

Controversy score = 1. Field consensus is broad. The genuine debates — subjective vs. objective definitional threshold, ferritin cutoff for symptom attribution, optimal first-line treatment between LNG-IUS and oral options — are real but minor and don't change the recognition-and-treat message.

Evidence score = 5. Two named RCTs (ECLIPSE, Lukes 2010), two named Cochrane reviews (2019 NSAIDs, 2020 LNG-IUS), aligned NICE + ACOG guidelines, 60-year population evidence backing the objective definition. Clears the "name 2+ rigorous trials" bar.